Dec 1 is day that this gem will shine and surprise everyone
S
Orchard Therapeutics Gets FDA Application Clearance for OTL-200 Therapy Dow Jones
M
Ready to Rocket to 15-20 in Jan Just the beginning
Z
I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
J
changed position to long now, reversal incoming.. +slowed burn rate +new programs in larger indications for FTD, Crohn’s and ALS +Insiders buying (RA, JPMorgan, Artisan) +catalysts for dec (EU-approval OTL-200+RMAT/IND FDA, Data ASH OTL-201) +touched double bottom @ $3.85
Another opportunity to exit with a jump from good news for short-term investors or people who cut their losses. You can wait for more jump until the result of the presidential election, and then, drop more than its rise. You can hold if you are interested in getting a big prize of at least 1 or 2 years later when their trials will show a more visible perspective of results.
Bearish
A
As expected, positive CHMP Opinion. Now let's run!!
Is there anyone who is trading in the US and was charged at 0.02 per ORTX stock? The company charges it when I am holding ORTX. I know the company is based in the UK.
J
This stock is tough to understand. Goes with the high risk high reward territory I guess. I’m riding it out.
Y
Orchard Therapeutics is up 10.00% to 4.62
A
Almost there.. CHMP opinion imminent:
"Orchard Therapeutics (Netherlands) BV; treatment of metachromatic leukodystrophy (MLD) Scope: oral explanation Action: oral explanation to be held on Wednesday, 07 October 2020 at 14:05hrs List of Outstanding Issues adopted on 11.09.2020. List of Questions adopted on 20.03.2020.
Oral explanation (section 2.2.) Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee. Committee for Advanced Therapies (CAT) EMA/CAT/531222/2020 Page 18/19 Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person."
Dow Jones
Just the beginning
+slowed burn rate
+new programs in larger indications for FTD, Crohn’s and ALS
+Insiders buying (RA, JPMorgan, Artisan)
+catalysts for dec (EU-approval OTL-200+RMAT/IND FDA, Data ASH OTL-201)
+touched double bottom @ $3.85
https://twitter.com/Mesmer21/status/1328179929826136067/photo/1
https://ir.orchard-tx.com/node/7731/pdf
"Orchard Therapeutics (Netherlands) BV; treatment of metachromatic leukodystrophy (MLD)
Scope: oral explanation
Action: oral explanation to be held on Wednesday, 07 October 2020 at 14:05hrs
List of Outstanding Issues adopted on 11.09.2020. List of Questions adopted on 20.03.2020.
Oral explanation (section 2.2.)
Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT
plenary meeting to address questions raised by the Committee.
Committee for Advanced Therapies (CAT)
EMA/CAT/531222/2020 Page 18/19
Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for
which the CAT would like to discuss with company representatives in person."
https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-7-9-october-2020-meeting_en.pdf